iHealthScreen

iHealthScreen is an AI-driven HIPAA-compliant med-tech company with incoming product traction in several international markets, using AI to Scalably Screen for Retinal Diseases, Stroke, and Heart Disease. Early diagnosis and intervention can prevent blindness, save countless lives & eliminate massive amounts of downstream spending. iHealthScreen is in the pre-revenue stage of development. Some of the information on the campaign page was obtained via the Company's relationship with iHealthScreen Ltd. (Abu Dhabi), which is an LLC, also owned by Alauddin Bhuiyan, PhD, CEO. There is a software license agreement between the two entities, allowing iHealthScreen Ltd. to use the Company's IP and software portfolios.

Alauddin Bhuiyan, PhDFounder and CEODr. Alauddin Bhuiyan is an inventor, innovator, and computer scientist with deep life science and medical technology expertise covering the spectrum of life science and med-tech. He is the founder and CEO of iHealthScreen Inc. and has been working in the retinal imaging and image-based disease screening area for more than 15 years. He has been with the company as full-time since January 2017. Before that, he was a faculty member in the department of Computer Science at New York University. He was a visiting scholar at Harvard Medical School and was the recipient of the prestigious Endeavor Australia Award 2014 and was recognized as a distinguished Australian. He has been holding an Adjunct Associate Professor position at New York Eye and Ear Infirmary, Icahn School of Medicine at Mount Sinai since July 01, 2019.
Dr. Bhuiyan led the developing iPredictTM a HIPAA-compliant AI-powered software tool, which is based on Electronic Health Record (EHR) and telemedicine platform to screen and predict individuals at risk of diabetic retinopathy (DR), Age-related Macular Degeneration (AMD), Glaucoma, heart disease and stroke (https://iPredict.health).
The AMD, DR, and glaucoma screening tools are already CE certified, Abu Dhabi Health and Australian Health approved.
Dr. Bhuiyan is the inventor of the first image-based prediction tool for age-related macular degeneration (AMD). A full US patent is awarded to iHealthScreen Inc. This work was selected as featured work at ARVO 2018, the largest ophthalmology conference in the world. Also, the American Academy of Ophthalmology selected his work for the panel discussion in 2020. His interview can be viewed at https://macularnews.org/2018/06/07/arvo-2018-alauddin-bhuiyan-phd/
Dr. Bhuiyan has received almost $5M Federal and state grants through various stages of his career. He secured more than $2.7M grants (another $2.2M is under consideration) for his company through NIH SBIR grants a Principal Investigator. 
Dr. Bhuiyan received his Ph.D. from the University of Melbourne, Australia, one of the top universities in the world (No. 1 in Australia). He joined at the Centre for Eye Research Australia (CERA) as a post-doctoral research fellow in 2009. Following this - in 2011, he joined at Commonwealth Scientific and Industrial Research Organization (CSIRO, which is the inventor of WiFi Technology) as a research scientist.
While at CSIRO, Dr. Bhuiyan developed a software tool that can predict an individual’s genetic association with Alzheimer’s disease, a patented technology currently being used by Neurovision.
As an innovator and technology developer, he has been at the core of medical products and technologies which have transformed the ophthalmic field and are impacting medical care for hundreds of thousands of patients every year.
Dr. Bhuiyan is a holder of multiple issued and pending patents. He has multiple high-impact publications in the field and published more than a hundred research articles, which have been cited by more than a thousand peer-reviewed publications. He is a senior member of IEEE Computer Society and IEEE Engineering in Medicine and Biology. He served on the technical committee for many IEEE conferences and journals., Travis Millman, MAPPStrategic AdvisorAs a startup veteran with a penchant for developing and launching breakthrough products, Travis has played many roles during the course of his career. He was as Chief Operating Officer at Neuvotion, an early-stage medical device startup working on a next generation approach to neuromuscular electrical stimulation. He has been working on everything from the headiest of strategy development and refinement to the block and tackling aspects of building and growing a company.
Travis works 1 hour per week on iHealthscreen
Ms. Kathleen Adams, MBA Chief Marketing OfficerThe clinical innovations patients need require integrating the benefits of several domains: biotech, pharma, diagnostics, genomics, and digital health. Having worked in all of these areas gives me the breadth and range to excel at cross-functional leadership, and the passion to keep the patient in mind. 

From market assessment to launch and implementation, I focus on new approaches to healthcare, particularly for life-threatening illnesses. Discoveries and inventions are essential, but not sufficient, to improving healthcare: closing the gap between new capabilities and the realities of care delivery is the only route to meaningful change for the better.

I nurture innovations -- new disease insights, new therapeutic or diagnostic technologies -- by working backward from the patient or provider, while others on the team work forward from the science. I've worked in marketing, business development, technology evaluation and patient advocacy roles at diagnostics companies, clinical laboratories and pharma and biotechnology companies, conducting pre-market evaluations, producing and executing development plans, and leading product launch campaigns for pharmaceutical and diagnostic products, as well as a suite of targeted diagnostic services. I've led commercial teams and strategic initiatives, served on a corporate board and a senior management team, and influenced at the senior executive level to bring about institutional change and enable new approaches to team-driven development.

My experience in establishing coalitions across the for-profit/not-for-profit divide, as well as my interdisciplinary team leadership efforts, are growing in relevance during this period of rapid industry restructuring and technology advancements. The explosion of health information and new technologies occurring simultaneously with the shift of decision-making responsibility to patients/consumers is driving change in a challenging way. The potential for more relevant, focused and personalized care is evident; the potential risks to patients without a deep understanding of science and medicine are daunting. Attention to health literacy, patient-centered research and implementation science are essential to help us optimize the benefits of new approaches. 
Ms. Kathleen Adams works 8-16 hours per week on iHealthscreen
Thomas Gerson, MBACFOThrough his decades of financial and business operations acumen in the life sciences covering such key functions as capital formation, strategic partnering, business development, and financial planning & analysis, Tom has the proven ability to identify and align an emerging growth company’s underlying capabilities with its most attractive commercialization opportunities thereby maximizing potential value creation and financial returns.
As a CFO, he raised more than $100M for his previous companies.